And presentation of Dr. Joshua M Bauml

1. Immune-Oncology:
A New Paradigm for
1st-line NSCLC
Mauricio Lema Medina MD
- Clínica de Oncología Astorga / Clínica SOMA, Medellín
A brief introduction

7. 2008
2012 2014
2016
Scagliotti
EURTAC PROFILE 1014
KN 24

8. Tasuku Honjo
Born 1942, Kyoto, Japan
A Cure Within
(Neil Canavan)

9. James Allison Tasuko Honjo
2018 Nobel Prize in Medicine – Cancer Immunotherapy

10. Survival
Time
Modified from Ribas A, et al. Clin Cancer Res.
2012;18:336-341.
Survival Pattern with Chemotherapy and Immune
checkpoint blockade
Immune checkpoint
Chemotherapy

11. 2008
2012 2014
2016
Scagliotti
EURTAC PROFILE 1014
KN 24
KN 189

13. Survival
Time
Inspired by Ribas A, et al. Clin Cancer Res.
2012;18:336-341.
Survival Pattern with Chemotherapy and Immune
checkpoint blockade
Immune checkpoint
+ Chemotherapy
Chemotherapy

15. PD-L1 expression in NSCLC

16. PD-L1 expression in NSCLC
KN 24
KN 189

23. Pembrolizumab +
Chemotherapy
improves OS
across ALL PD-L1
expression levels
in non-squamous
NSCLC

24. KN 407 (Paz-Ares L, NEJM, 2018)
HR for OS for the trial: 0.64

25. Pembrolizumab +
Chemotherapy
improves OS
across ALL PD-L1
expression levels
in non-squamous
AND squamous
NSCLC

26. Joshua M. Bauml, MD
Assistant Professor of Medicine at the
Hospital of the University of
Pennsylvania and the Veteran's
Administration Medical Center
Medical School: Mount Sinai School of Medicine
Residency: Mount Sinai Medical Center
Fellowship: Hospital of the University of Pennsylvania
Bauml J, Aggarwal C, Evans TL, Ciunci C, Miller L, Muhammad N, Mutale F, Knepley C, Langer CJ, Cohen RB.: Oligometastatic Disease in Cancer: Broadening the Path to
Cure? Journal of Targeted Therapies in Cancer : 2018.
Aggarwal C, Davis CW, Mick R, Thompson JC, Ahmed S, Jeffries S, Bagley S, Gabriel P, Evans TL, Bauml JM, Ciunci C, Alley E, Morrissette JJD, Cohen RB, Carpenter
EL, Langer CJ: Influence of TP53 Mutation on Survival in Patients with Advanced EGFR-Mutant Non-Small-Cell Lung Cancer JCO Precision Oncology : 2018.
Bauml JM, Vinnakota R, Park YHA, Bates SE, Fojo T, Aggarwal C, DiStefano J, Knepley C, Limaye S, Mamtani R, Wisnivesky JP, Damjanov N, Langer CJ, Cohen RB,
Sigel K: Cisplatin Versus Cetuximab with Definitive Concurrent Radiotherapy for Head and Neck Squamous Cell Carcinoma: an Analysis of Veteran’s Health Data Cancer : 2018.
Romero SAD, Brown JC, Bauml JM, Hay JL, Li QS, Cohen RB, Mao JJ: Barriers to physical activity: a study of academic and community cancer survivors with pain Journal of
Cancer Survivorship 66 (4): 2018.
Katz SI, Hammer M, Bagley SJ, Aggarwal C, Bauml JM, Thompson JC, Nachiappan AC, Simone CB, Langer CJ: Radiologic Pseudoprogression during Anti-PD-1 Therapy for
Advanced Non-Small Cell Lung Cancer Journal of Thoracic Oncology 13 (7): 2018.
Bauml J, Levy B: Clonal Hematopoiesis: A New Layer in the Liquid Biopsy Story in Lung Cancer CCR : 2018.
Romero SAD, Jones L, Bauml JM, Li QS, Cohen RB, Mao JJ.: The association between fatigue and pain symptoms and decreased physical activity after cancerSupportive Care
in Cancer 32 (17): 2018.
Hammer M, Bagley S, Aggarwal C, Bauml J, Nachiappan AC, Simone CB 2nd, Langer C, Katz SI: Thoracic Imaging of Non-Small Cell Lung Cancer Treated with Anti-
programmed Death Receptor-1 Therapy Curr Probl Diagn Radiol : 2018.
Bauml J, Mick R, Ciunci C, Aggarwal C, Evans T, Miller L, Muhammad N, Alley E, Knepley C, Mutale F, Cohen RB, Langer CJ. “: Phase II Study of Pembrolizumab for
Oligometastatic Non-Small Cell Lung Cancer (NSCLC) Following Completion of Locally Ablative Therapy (LAT) Oral Presentation at World Conference On Lung Cancer : 2018.
Bauml JM, Vinnakota R, Park YHA, Bates SE, Fojo T, Aggarwal C, Limaye S, Damjanov N, DiStefano J, Ciunci C, Genden EM, Wisnivesky JP, Ferrandino R, Mamtani R,
Langer CJ, Cohen RB, Sigel K.: Cisplatin Every 3 Weeks Versus Weekly With Definitive Concurrent Radiotherapy for Squamous Cell Carcinoma of the Head and Neck Journal of
the National Cancer Institute 65 (8): 2018.
Center for Head and Neck Cancer
Lung Cancer